KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Gilead Sciences (GILD) Enterprise Value (2016 - 2026)

Gilead Sciences filings provide 17 years of Enterprise Value readings, the most recent being -$7.7 billion for Q4 2025.

  • On a quarterly basis, Enterprise Value rose 23.41% to -$7.7 billion in Q4 2025 year-over-year; TTM through Dec 2025 was -$7.7 billion, a 23.41% increase, with the full-year FY2025 number at -$7.7 billion, up 23.41% from a year prior.
  • Enterprise Value hit -$7.7 billion in Q4 2025 for Gilead Sciences, down from -$7.4 billion in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$2.9 billion in Q2 2024 to a low of -$10.1 billion in Q4 2024.
  • Median Enterprise Value over the past 5 years was -$6.2 billion (2022), compared with a mean of -$6.3 billion.
  • Biggest five-year swings in Enterprise Value: soared 76.04% in 2021 and later tumbled 85.47% in 2025.
  • Gilead Sciences' Enterprise Value stood at -$6.5 billion in 2021, then increased by 1.67% to -$6.4 billion in 2022, then decreased by 14.53% to -$7.3 billion in 2023, then crashed by 37.11% to -$10.1 billion in 2024, then rose by 23.41% to -$7.7 billion in 2025.
  • The last three reported values for Enterprise Value were -$7.7 billion (Q4 2025), -$7.4 billion (Q3 2025), and -$5.3 billion (Q2 2025) per Business Quant data.